European Journal of Clinical Microbiology

, Volume 5, Issue 1, pp 29–34 | Cite as

Factors influencing the activity of the trometamol salt of fosfomycin

  • D. Greenwood
  • A. Jones
  • A. Eley
Articles

Abstract

The antibacterial activity of trometamol fosfomycin and its potentiation by glucose-6-phosphate were found to vary considerably in different culture media, although not all bacteria tested were equally affected. In general, the lowest MICs were obtained in the presence of glucose-6-phosphate in nutrient broth and Eugonbroth. The influence of inoculum size, pH and potentiation by glucose-6-phosphate were investigated by agar incorporation MIC titrations on nutrient agar. The activity of trometamol fosfomycin against many strains increased as the pH was lowered from 7.9 to 5.5. Only 9% of the strains showed an inoculum effect when tested at pH 5.5 in the presence of glucose-6-phosphate compared with 37% of the strains tested at pH 7.1 and 22% of the strains tested at pH 7.9. In the absence of glucose-6-phosphate, about 10% of the strains showed an inoculum effect at all three pH levels. The addition of glucose-6-phosphate to culture media seems reasonable for the testing of fosfomycin susceptibility.

Keywords

Internal Medicine Agar Antibacterial Activity Nutrient Agar Nutrient Broth 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Hendlin, D., Stapley, E. O., Jackson, M., Wallick, H., Miller, A. K., Wolf, F. J., Miller, T. W., Chaiet, L., Kahan, F. M., Foltz, E. L., Woodruff, H. B., Mata, J. M., Hernandez, S., Mochales, S.: Phosphonomycin, a new antibiotic produced by strains of Streptomyces. Science 1969, 166: 122–123.PubMedGoogle Scholar
  2. 2.
    Kahan, F. M., Kahan, J. S., Cassidy, P. J., Kropp, H.: The mechanism of action of fosfomycin (phosphonomycin). Annals of the New York Academy of Sciences 1974, 235: 364–386.PubMedGoogle Scholar
  3. 3.
    Kirby, W.M.M.: Pharmacokinetics of fosfomycin. Chemotherapy 1977, 23, Supplement 1: 141–151.PubMedGoogle Scholar
  4. 4.
    Ferrari, V., Bonanomi, L., Borgia, M., Lodola, E., Marca, G.: A new fosfomycin derivative with much improved bioavailability by oral route. Chemioterapia Antimicrobica 1981, 4: 59–63.Google Scholar
  5. 5.
    Greenwood, D., O'Grady, F.: Comparison of the responses ofEscherichia coli andProteus mirabilis to sevenβ-lactam antibiotics. Journal of Infectious Diseases 1973, 128: 211–222.PubMedGoogle Scholar
  6. 6.
    Zimmerman, S. B., Stapley, E. O., Wallick, H., Baldwin, R.: Phosphonomycin IV. Susceptibility testing method and survey. In: Hobby, G. L. (ed.): Antimicrobial Agents and Chemotherapy-1969. American Society for Microbiology, Bethesda, Maryland, 1970, p. 303–309.Google Scholar
  7. 7.
    Andrews, J. M., Baquero, F., Beltran, J. M., Canton, E., Crokaert, F., Gobernado, M., Gomez-Lus, R., Loza, E., Navarro, M., Olay, T., Rodriguez, A., Vicente, M. V., Wise, R., Yourassowsky, E.: International collaborative study on standardization of bacterial sensitivity to fosfomycin. Journal of Antimicrobial Chemotherapy 1983, 12: 357–361.Google Scholar
  8. 8.
    Haag, R., Vömel, W.: Einflüsse auf die Aktivität von Fosfomycin in vitro. Immunität und Infektion 1979, 7: 202–209.Google Scholar

Copyright information

© Friedr. Vieweg & Sohn Verlagsgesellschaft mbH 1986

Authors and Affiliations

  • D. Greenwood
    • 1
  • A. Jones
    • 1
  • A. Eley
    • 1
  1. 1.Department of Microbiology and PHLS LaboratoryUniversity Hospital, Queen's Medical CentreNottinghamUK

Personalised recommendations